Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea

Advanced Capsule Technology for Improved Digestive Enzyme Delivery

SEOUL, South Korea, Aug. 5, 2026 /PRNewswire/ -- Lonza Capsugel has released new peer-reviewed research showing that its Licaps^® DUOCAP^® capsule-in-capsule technology can significantly improve the protection and targeted delivery of acid-sensitive enzymes in the gastrointestinal (GI) tract. Conducted in collaboration with ProDigest (Belgium), leading experts in preclinical gastrointestinal tract models, the study highlights the impact of dual-release capsule technologies in unlocking advanced product development opportunities and reinforces the importance of delivery choice for nutraceutical products

Published in Pharmaceutics, the study used the Simulator of the Human Intestinal Microbial Ecosystem (SHIME)^® in vitro model to compare multiple capsule polymers and formulations under realistic fed and fasted digestive conditions. To assess dissolution behavior, capsules contained caffeine as a marker of capsule dissolution, as well as pancreatin, an acid-sensitive digestive enzyme that is converted from tributyrin to butyrate when it reaches the upper small intestine. Five capsule formulations, including two single capsule types and three Licaps^® DUOCAP^® capsule-in-capsule configurations, were assessed for dissolution timing, ingredient protection and enzyme activity throughout the upper gastrointestinal tract, with particular focus on the upper small intestine where digestive enzymes are most effective.

When taken with food, the Licaps^® DUOCAP^® capsule-in-capsule formulations demonstrated superior protection and targeted release profiles, with caffeine released at the end of the duodenum and/or jejunum and a high butyrate recovery, ranging from 53% to 87%. Enzyme activity was up to four times higher in the upper small intestine compared to standard immediate-release capsules. In contrast, the immediate-release single capsule format released a high level of its contents in the stomach, as shown by low butyrate recovery in the upper small intestine (16–21%). This suggests gastric degradation of the unprotected enzyme, meaning that the intended delivery was significantly impaired when compared to the Licaps^® DUOCAP^® capsule-in-capsule technology.

Dr. Elnaz Karimian Azari, Senior Manager R&D, Lonza Capsugel and lead author of the study, said:

"This study further reinforces the robustness and reliability of our Licaps^® DUOCAP^® capsule-in-capsule technology, providing independent, peer-reviewed validation of its ability to deliver sensitive ingredients to targeted regions of the gastrointestinal tract. While this work focused on release in the upper small intestine, it builds on a growing body of evidence demonstrating that Licaps^® DUOCAP^® capsules can protect and transport ingredients like live probiotics all the way to the colon, where they are needed to achieve optimal performance. It also highlights just how important capsule selection is to the success and effectiveness of nutraceutical products – and why delivery really does matter."

Experience the Future of Oral Delivery at CPHI Korea 2026

As one of Asia's premier pharmaceutical and nutraceutical industry events, CPHI Korea 2026 brings together innovators, formulators, manufacturers, and industry leaders to explore the latest advancements shaping the future of healthcare and nutrition. The event serves as a key platform for networking, knowledge exchange, and discovering breakthrough technologies that enable next-generation product development

Join our experts at Booth K15, COEX, Seoul, South Korea, from 25-27 August 2026, to explore the latest scientific advancements in targeted ingredient delivery, discuss your formulation challenges, and learn how innovative capsule technologies can accelerate your next product innovation. Whether you are developing digestive health solutions, probiotics, oral biologics, or next-generation nutraceutical products, our team will be available to share insights and collaborate on tailored delivery strategies.

For more information on Licaps® DUOCAP® capsule-in-capsule technology, please visit us at CPHI Korea or contact us at solutions.apac@lonza.com. 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea

NAPLES, Italy, Aug. 6, 2026 /PRNewswire/ -- Zoomlion's DV3504 hybrid tractor has been shortlisted for two categories of the prestigious Tractor of the Year 2027 (TOTY 2027) awards: HighPower (300 hp and above) and Sustainable.

Launched in 1998 and independently organised by Italy's agricultural machinery publication Trattori, TOTY is one of the most recognised professional awards in the global agricultural machinery industry. The 2027 edition attracted 23 tractors from 18 global brands, with evaluations conducted by an international jury of 26 independent agricultural machinery journalists from 25 countries.

The dual-category nomination represents a milestone for Chinese agricultural machinery. The DV3504 is the first Chinese high-horsepower tractor to enter the TOTY shortlist since the award's establishment, breaking a long-standing gap for Chinese heavy-duty tractors in this globally influential competition. It is also the first Chinese high-horsepower agricultural machine recognised by an international independent jury for its original hybrid and low-carbon technology solution.

Developed to meet the demands of large-scale farming operations, the DV3504 delivers 350 hp and is equipped with Zoomlion's self-developed MiDD (Meshed intelligent Direct Drive) distributed intelligent electric drive system. Based on a multi-motor direct-drive architecture, the system independently powers the tractor's travel, PTO and hydraulic functions, enabling modular continuously variable transmission while reducing mechanical transmission components by approximately 70%.

Unlike pure electric solutions that still face challenges in endurance and continuous high-load operation for heavy-duty agricultural applications, hybrid technology provides a balance of long operating range, strong power output and energy efficiency. The DV3504 reflects Zoomlion's strategic focus on hybrid power and intelligent technologies for premium agricultural equipment.

Leveraging technological capabilities accumulated from its construction machinery business, including new energy systems, intelligent control and advanced manufacturing, Zoomlion is accelerating the transformation of agricultural machinery toward higher performance and sustainability.

Following its debut at AGRITECHNICA 2025 in Hanover, Germany, Zoomlion has achieved a significant step forward in its global agricultural machinery expansion — moving from an international exhibitor to a shortlisted contender in a leading global industry award within one year.

The final winners of TOTY 2027 will be announced at EIMA International in Bologna in November 2026.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Zoomlion DV3504 Hybrid Tractor Shortlisted for Two Categories of TOTY 2027, Marking a Breakthrough for Chinese High-Horsepower Agricultural Machinery